Post-marketing withdrawal of analgesic medications because of adverse drug reactions: a systematic review

Journal article

Introduction

Many analgesics have been withdrawn from the market because of adverse drug reactions. Controversy still surrounds the use of some approved analgesics for pain management. However, the trends and reasons for withdrawal of analgesics when harms are attributed to their use have not been systematically assessed.

Areas covered

We conducted searches in PubMed; Embase; Google Scholar; clinicaltrials.gov; WHO databases of withdrawn products; websites of the European Medicines Agency, the US Food and Drug Administration, the UK Medicines and Healthcare products Regulatory Agency; Meyler’s Side Effects of Drugs; Stephens’ Detection of New Adverse Drug Reactions; the Pharmaceutical Manufacturing Encyclopedia; and the Merck Index. We included licensed analgesics that were withdrawn after marketing because of adverse reactions between 1950 and March 2017. We excluded herbal products, non-human medicines, and non-prescription medicines. We used the Oxford Centre for Evidence Based Medicine criteria to document the levels of evidence, and chi-squared tests to compare withdrawal patterns across geographical regions.

Expert opinion

Pharmacovigilance systems in low-resource settings should be strengthened. Greater co-ordination across regulatory authorities in assessing and interpreting the benefit-harm balance of new analgesics should be encouraged. Future reporting of harms in clinical trials of analgesics should follow standardized guidelines.

Authors: Onakpoya, I; Heneghan, C; Aronson, J

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Taylor and Francis
• Journal: Expert Opinion on Drug Safety
• Volume: 17
• Issue: 1
• Pages: 63-72
• Publication date: 2017-10-27
• Acceptance date: 2017-10-24
• DOI: 10.1080/14740338.2018.1398232
• EISSN: 1744-764X
• ISSN: 1474-0338
• Pmid: 29076385
• Language: English
• Keywords: humans; guidelines as topic; safety-based drug withdrawals; pharmacovigilance; analgesics; product surveillance, postmarketing; pain; adverse drug reaction reporting systems